Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Destiny Pharma PLC (Aim:DEST) (Destiny Pharma PLC (Aim:DEST)) is a scientific phase, modern biotechnology organization targeted on the growth of novel medicines that can reduce lifestyle-threatening bacterial infections. The company’s pipeline has novel microbiome-dependent biotherapeutics and XF drug scientific belongings together with NTCD-M3, a Stage three prepared treatment for the avoidance of C. difficile infection (CDI) recurrence which is the top induce of clinic acquired bacterial infections in the US. Destiny’s pipeline also includes XF-seventy three nasal gel, which has not too long ago completed a positive Stage 2b scientific demo targeting the avoidance of submit-surgical staphylococcal clinic bacterial infections together with MRSA. The organization is also co-building SPOR-COV, a novel, biotherapeutic solution for the avoidance of COVID-19 and other viral respiratory bacterial infections.